PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Petent & Tratemark Office: U.S. DEPARTMENT OF COMMERCE
on of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 09/847041 STATEMENT BY APPLICANT May 1, 2001 **Filing Date** (Use as many sheets as necessa Linsell, Martin **First Named Inventor** MAY 0 6 2002 **Group Art Unit** Unknown **Examiner Name** Unknown Attorney Docket No: 01343.001US1 Sheet 1 of 1

US PATENT DOCUMENTS												
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate						

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²			
	WO-00/54751	09/21/2000	Berndt, Gunther, et al						
	WO-01/97851 .	03/13/2002	Choi, Seung-Ho, et al						
	WO-01/98326	12/27/2001	Mu, YongQi						
	WO-01/98327 -	12/27/2001	Linsell, Martin , et al						
	WO-01/98328 °	12/27/2001	Leadbetter, M.R., et al						
	WO-01/98329	12/27/2001	Yang, Guang, et al						
	WO-94/12217	06/09/1994	Tsao, Sheng-Wan, et al						

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			



RECEIVED TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Martin S. Linsell et al.

Title:

POLYACID GLYCOPEPTIDE DERIVATIVES

Docket No.: Filed:

1343.001US1

May 1, 2001

Examiner:

Unknown

Serial No.: 09/847,041

Due Date: N/A

Group Art Unit: Unknown

Commissioner for Patents Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

<u>X</u> <u>X</u> A return postcard.

A Supplemental Information Disclosure Statement (1 pg.), Form 1449 (1 pg.), and copies of 7 cited references.

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Atty: Robert J. Harris, Ph.D.

Reg. No. 37,346

©ERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States If ostal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this April, 2002.

Alisia G. Dunbar

Name

Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)

S/N 09/847,041

IN THE UNITED STATES ND TRADEMARK OFFICE

Applicant:

Martin S. Linsell et al.

Serial No.:

09/847,041

Filed: Title:

May 1, 2001 <

POLYACID GLYCOPEPTIDE DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAY 0 6 2002

Examiner: Unknown

Group Art Unit: Unknown

Docket: 1343.001US1

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. sea., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application.

Applicants are submitting herewith International Patent Application Publication Number WO 00/54751 (in German) with an English abstract included on the front page. Applicants submit that the English abstract is a concise explanation of the relevance of International Patent Application Publication Number WO 00/54751, as required under 37 C.F.R. 1.98(a)(3). Accordingly, the Examiner is respectfully requested to acknowledge consideration of International Patent Application Publication Number WO 00/54751.

Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed. the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representatives at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

MARTIN S. LINSELL ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938

Minneapolis, MN 55402 (612) 359-3265

Date _ 4-30-02

Dunbar

Robert J. Harris, Ph.D. Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 20 thay of April, 2002.

Name

Signature